AstraZeneca plc (LON:AZN) had its target price hoisted by Berenberg Bank from GBX 5,450 ($68.60) to GBX 5,670 ($71.37) in a research note issued to investors on Monday morning. Berenberg Bank currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities analysts also recently weighed in on the company. Deutsche Bank AG reissued a buy rating and set a GBX 6,000 ($75.52) target price on shares of AstraZeneca plc in a research report on Wednesday, November 30th. Bryan, Garnier & Co reissued a buy rating and set a GBX 5,100 ($64.19) target price on shares of AstraZeneca plc in a research report on Tuesday, November 22nd. Jefferies Group LLC reissued a buy rating and set a GBX 5,400 ($67.97) target price (down previously from GBX 5,600 ($70.48)) on shares of AstraZeneca plc in a research report on Monday, December 19th. Goldman Sachs Group Inc set a GBX 3,900 ($49.09) price objective on AstraZeneca plc and gave the company a sell rating in a research report on Friday, February 3rd. Finally, JPMorgan Chase & Co. reaffirmed a neutral rating and issued a GBX 4,600 ($57.90) price objective on shares of AstraZeneca plc in a research report on Tuesday, December 6th. Five research analysts have rated the stock with a sell rating, six have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average target price of GBX 5,057.40 ($63.66).

AstraZeneca plc (LON:AZN) opened at 4566.00 on Monday. The firm has a 50-day moving average of GBX 4,808.85 and a 200 day moving average of GBX 4,576.87. AstraZeneca plc has a 12-month low of GBX 3,680.00 and a 12-month high of GBX 5,505.00. The company’s market capitalization is GBX 57.77 billion.

TRADEMARK VIOLATION NOTICE: “Berenberg Bank Boosts AstraZeneca plc (AZN) Price Target to GBX 5,670” was reported by Marea Informative and is the sole property of of Marea Informative. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at http://www.mareainformativa.com/berenberg-bank-eleva-astrazeneca-plc-azn-precio-objetivo-a-gbx-5670/108849/.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.